MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Benefits of Physician-Pharmacist Collaboration on Patient Outcomes in Parkinson’s Disease and Movement Disorders Clinic

P. Techa-Angkoon, Y. Pitakpatapee, W. Saengphatrachai, P. Srivanitchapoom, T. Suansanae (Bangkok, Thailand)

Meeting: 2023 International Congress

Abstract Number: 134

Keywords: Parkinson’s

Category: Parkinson’s Disease: Clinical Trials

Objective: To evaluate the impact of pharmacist participation in Parkinson’s disease and movement disorders clinic on the number of drug-related problems (DRPs), clinical outcomes, and the quality of life of patients with Parkinson’s disease (PD).

Background: Most patients with PD commonly receive many medications for the management of both motor and non-motor symptoms, including several comorbidities. It might lead to DRPs, which may decrease the likelihood of achieving the desired therapeutic outcome. Although pharmaceutical care seems to improve adherence and the quality of life in PD patients, evidence regarding the impact of pharmaceutical care on therapeutic outcomes in PD patients remains to be clearly elucidated particularly in randomized controlled trials.

Method: A randomized controlled study was conducted in patients with idiopathic PD of the Parkinson’s Disease and Movement Disorders Outpatient Clinic at Siriraj Hospital, Thailand. Participants were randomly assigned (1:1) to the physician-pharmacist group or the usual care group. The primary outcome was changes in number of DRPs from baseline to 24 weeks between the two groups. Secondary outcomes included number of DRPs related to PD treatment, clinical outcomes (Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale, MDS-UPDRS), clinical status (Patients’ Global Impression of Change, PGIC), and quality of life (Parkinson’s Disease Questionnaire, PDQ-8). The participants and assessors evaluating the MDS-UPDRS were blinded.

Results: A total of 80 patients were randomized into physician-pharmacist group (n=40) and usual care group (n=40). The changes in the number of DRPs in physician-pharmacist group improved significantly when compared to usual care group (-7.3±3.6 and -2.9±1.9, respectively; p<0.001), especially non-adherence issues. Likewise, secondary outcomes also improved significantly in the physician-pharmacist group at 24 weeks in comparison to usual care group; the change in the number of DRPs related to PD treatment (p <0.001), MDS-UPDRS total score (p <0.001), PGIC (p = 0.003) PDQ-8 (p <0.001). No significant differences were found between groups in MDS-UPDRS-III.

Conclusion: Our findings demonstrated that physician-pharmacist collaboration service in the PD and movement disorder clinic had a positive impact on patient outcomes.

To cite this abstract in AMA style:

P. Techa-Angkoon, Y. Pitakpatapee, W. Saengphatrachai, P. Srivanitchapoom, T. Suansanae. Benefits of Physician-Pharmacist Collaboration on Patient Outcomes in Parkinson’s Disease and Movement Disorders Clinic [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/benefits-of-physician-pharmacist-collaboration-on-patient-outcomes-in-parkinsons-disease-and-movement-disorders-clinic/. Accessed May 24, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/benefits-of-physician-pharmacist-collaboration-on-patient-outcomes-in-parkinsons-disease-and-movement-disorders-clinic/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley